Candriam S.C.A. Fibrogen Inc Call Options Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding FGEN
# of Institutions
84Shares Held
47.9MCall Options Held
387KPut Options Held
672K-
Primecap Management CO Pasadena, CA9.91MShares$3.67 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY6.8MShares$2.52 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.88MShares$2.18 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA3.91MShares$1.44 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.41MShares$891,5700.0% of portfolio
About FIBROGEN INC
- Ticker FGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 93,741,200
- Market Cap $34.7M
- Description
- FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...